Tirzepatide cuts diabetes risk by 94%

(CNN)– Eli Lilly says a popular type two diabetes medication could help prevent the progression of the disease.

The drug company says Tirzepatide cuts the risk of progression to diabetes by 94% in adults with pre-diabetes and obesity.

The medication is approved in the U.S. as Mounjaro for diabetes and Zepbound for weight loss.

The three year study also found people who took the injectable drug weekly had an average decrease in body weight of nearly 23%.

That’s compared with just over 2% in those who got a placebo.